Cargando…
Treatment of Inflammatory Bowel Disease and Pediatric Onset Multiple Sclerosis With Ocrelizumab and Ustekinumab in a JC-virus Positive Adolescent
Inflammatory bowel disease (IBD) and multiple sclerosis (MS) are known to co-occur. Many disease modifying therapies for MS may exacerbate IBD and several carry risk of progressive multifocal leukoencephalopathy in JC-virus (JCV) positive patients. Some biologics used for IBD can exacerbate MS. Thes...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158457/ https://www.ncbi.nlm.nih.gov/pubmed/37168621 http://dx.doi.org/10.1097/PG9.0000000000000214 |
_version_ | 1785036933974458368 |
---|---|
author | Lambert-Jenkins, Kristin Rossman, Ian Watson, Kevin L |
author_facet | Lambert-Jenkins, Kristin Rossman, Ian Watson, Kevin L |
author_sort | Lambert-Jenkins, Kristin |
collection | PubMed |
description | Inflammatory bowel disease (IBD) and multiple sclerosis (MS) are known to co-occur. Many disease modifying therapies for MS may exacerbate IBD and several carry risk of progressive multifocal leukoencephalopathy in JC-virus (JCV) positive patients. Some biologics used for IBD can exacerbate MS. These factors make comanagement of these diseases difficult. We report a 17-year-old female who presented with right leg weakness and paresthesia and was diagnosed with pediatric onset MS (POMS). She then had worsening abdominal pain and diarrhea, accompanied by weight loss, and was subsequently diagnosed with Crohn’s disease. She was weakly JCV positive, so a short trial of natalizumab was initiated, which controlled her POMS well but not her IBD. Ustekinumab and ocrelizumab were initiated and achieved remission of both diseases. In the absence of established treatment guidelines, we recommend considering this combination of therapies for cases where standard treatment modalities are not viable options. |
format | Online Article Text |
id | pubmed-10158457 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101584572023-05-09 Treatment of Inflammatory Bowel Disease and Pediatric Onset Multiple Sclerosis With Ocrelizumab and Ustekinumab in a JC-virus Positive Adolescent Lambert-Jenkins, Kristin Rossman, Ian Watson, Kevin L JPGN Rep Case Report Inflammatory bowel disease (IBD) and multiple sclerosis (MS) are known to co-occur. Many disease modifying therapies for MS may exacerbate IBD and several carry risk of progressive multifocal leukoencephalopathy in JC-virus (JCV) positive patients. Some biologics used for IBD can exacerbate MS. These factors make comanagement of these diseases difficult. We report a 17-year-old female who presented with right leg weakness and paresthesia and was diagnosed with pediatric onset MS (POMS). She then had worsening abdominal pain and diarrhea, accompanied by weight loss, and was subsequently diagnosed with Crohn’s disease. She was weakly JCV positive, so a short trial of natalizumab was initiated, which controlled her POMS well but not her IBD. Ustekinumab and ocrelizumab were initiated and achieved remission of both diseases. In the absence of established treatment guidelines, we recommend considering this combination of therapies for cases where standard treatment modalities are not viable options. Lippincott Williams & Wilkins, Inc. 2022-06-21 /pmc/articles/PMC10158457/ /pubmed/37168621 http://dx.doi.org/10.1097/PG9.0000000000000214 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Case Report Lambert-Jenkins, Kristin Rossman, Ian Watson, Kevin L Treatment of Inflammatory Bowel Disease and Pediatric Onset Multiple Sclerosis With Ocrelizumab and Ustekinumab in a JC-virus Positive Adolescent |
title | Treatment of Inflammatory Bowel Disease and Pediatric Onset Multiple Sclerosis With Ocrelizumab and Ustekinumab in a JC-virus Positive Adolescent |
title_full | Treatment of Inflammatory Bowel Disease and Pediatric Onset Multiple Sclerosis With Ocrelizumab and Ustekinumab in a JC-virus Positive Adolescent |
title_fullStr | Treatment of Inflammatory Bowel Disease and Pediatric Onset Multiple Sclerosis With Ocrelizumab and Ustekinumab in a JC-virus Positive Adolescent |
title_full_unstemmed | Treatment of Inflammatory Bowel Disease and Pediatric Onset Multiple Sclerosis With Ocrelizumab and Ustekinumab in a JC-virus Positive Adolescent |
title_short | Treatment of Inflammatory Bowel Disease and Pediatric Onset Multiple Sclerosis With Ocrelizumab and Ustekinumab in a JC-virus Positive Adolescent |
title_sort | treatment of inflammatory bowel disease and pediatric onset multiple sclerosis with ocrelizumab and ustekinumab in a jc-virus positive adolescent |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158457/ https://www.ncbi.nlm.nih.gov/pubmed/37168621 http://dx.doi.org/10.1097/PG9.0000000000000214 |
work_keys_str_mv | AT lambertjenkinskristin treatmentofinflammatoryboweldiseaseandpediatriconsetmultiplesclerosiswithocrelizumabandustekinumabinajcviruspositiveadolescent AT rossmanian treatmentofinflammatoryboweldiseaseandpediatriconsetmultiplesclerosiswithocrelizumabandustekinumabinajcviruspositiveadolescent AT watsonkevinl treatmentofinflammatoryboweldiseaseandpediatriconsetmultiplesclerosiswithocrelizumabandustekinumabinajcviruspositiveadolescent |